These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31991336)

  • 1. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
    Yun F; Cheng C; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Jul; 198():112322. PubMed ID: 32361064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.
    Saidahmatov A; Li J; Xu S; Hu X; Gao X; Kan W; Gao L; Li C; Shi Y; Sheng L; Wang P; Zhou Y; Liang X; Li J; Liu H
    J Med Chem; 2024 Sep; 67(17):15220-15245. PubMed ID: 39178382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
    Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
    Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.
    Zhang C; Lundgren K; Yan Z; Arango ME; Price S; Huber A; Higgins J; Troche G; Skaptason J; Koudriakova T; Nonomiya J; Yang M; O'Connor P; Bender S; Los G; Lewis C; Jessen B
    Mol Cancer Ther; 2008 Apr; 7(4):818-28. PubMed ID: 18413795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
    Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
    Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
    Hirata Y; Hirata M; Kawaratani Y; Shibano M; Taniguchi M; Yasuda M; Ohmomo Y; Nagaoka Y; Baba K; Uesato S
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1926-30. PubMed ID: 22321215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.
    Ding Q; Liu C; Zhao C; Dong H; Xu Q; James Chou C; Zhang Y
    Bioorg Chem; 2020 Nov; 104():104235. PubMed ID: 32896808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.